Situation: A 63-year-old man with a deep vein thrombosis of the left leg is being discharged on warfarin because a direct oral anticoagulant is not affordable for him. He lives alone, prepares his own meals, and will have his international normalized ratio (INR) checked weekly at the outpatient clinic. He asks, "Why do I need a blood test every week when my tablet dose is already written down?" Which explanation should the nurse give?

The response to warfarin differs between people and changes with other drugs, diet, and illness. The INR measures how long the blood takes to clot, and the dose is adjusted to keep it in the target range. It does not measure clot size, liver injury, or platelets.

The INR is a laboratory value that reflects how long it takes the blood to form a clot. In a patient taking warfarin, the goal is not simply to give a fixed milligram dose, but to achieve a specific intensity of anticoagulation. Because warfarin has a narrow therapeutic window, the same dose can produce very different effects from person to person and even within the same person over time.

Warfarin works by inhibiting vitamin K–dependent clotting factors (II, VII, IX, and X). The international normalized ratio (INR) is calculated from the prothrombin time (PT) and standardizes results across different laboratories and reagent systems. The INR does not measure the size of the clot, liver enzyme levels, or the platelet count. It measures the functional activity of the extrinsic and common coagulation pathways, which is precisely what warfarin alters.

The reason weekly monitoring is required even when the tablet dose is “already written down” is that warfarin’s effect is highly variable. Dietary vitamin K intake, other medications, liver function, acute illness, and genetic differences in drug metabolism all shift the dose–response relationship. A dose that produces a therapeutic INR one week may produce a subtherapeutic or dangerously supratherapeutic INR the next week. The INR is therefore used to titrate the dose, not to confirm that a fixed dose was taken.

Key point! An INR below the target range means the patient remains at risk for clot extension or new thromboembolism, while an INR above the range increases the risk of major bleeding. The test result guides dose adjustment before either complication occurs.

The role of routine INR monitoring is reinforced by the available evidence. A performance improvement initiative in hospitalized patients emphasized that adverse drug events related to warfarin, particularly bleeding, are common and that structured processes for monitoring are needed to ensure safe use ^[1]. Studies evaluating warfarin management by pharmacists and by nursing staff using point-of-care INR testing also describe INR control as the central measure of whether anticoagulation is safe and effective ^[3][4]. In aged-care settings, suboptimal INR control was identified as a clinical problem requiring better monitoring systems, not simply better written prescriptions ^[4]. A telehealth intervention for patients on long-term warfarin similarly used INR results as the primary indicator for ongoing management .

The distractors in this question each describe a different laboratory test. Liver injury from warfarin would be assessed with alanine aminotransferase (ALT), aspartate aminotransferase (AST), or bilirubin, not the INR. A falling platelet count would be detected with a complete blood count (CBC), and while warfarin can rarely cause immune-mediated thrombocytopenia, the INR does not count platelets. Clot dissolution is not measured by any routine blood test; it is assessed clinically through symptom resolution and imaging such as venous duplex ultrasonography.

Watch out! A common exam error is to associate any anticoagulant-related blood test with “checking the clot.” The INR is a pharmacodynamic measure of warfarin’s anticoagulant effect, not an anatomical measure of thrombus burden.

For this patient, the explanation should be practical: the weekly INR tells the healthcare team whether the current warfarin dose is producing the desired level of anticoagulation. If the INR is too low, the dose is increased; if too high, the dose is reduced or held. The target INR for most patients with deep vein thrombosis is 2.0 to 3.0. Values below 2.0 indicate insufficient anticoagulation, and values above 3.0 indicate an increased bleeding risk. The same milligram dose can fall anywhere in or outside that range depending on the factors mentioned above, which is why the blood test is repeated rather than assumed to be stable.